How to buy Virax Biolabs Group stock (VRAX)

Virax Biolabs Group is a biotechnology business based in the US. Virax Biolabs Group shares (VRAX) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $1.70 – the same closing value as a week prior. Virax Biolabs Group employs 17 staff and has a trailing 12-month revenue of around $156,419.

Our top picks for where to buy Virax Biolabs Group Limited Ordinary Shares stock

Buy Virax Biolabs Group stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

Virax Biolabs Group stock price (NASDAQ: VRAX)

Use our graph to track the performance of VRAX stocks over time.

Virax Biolabs Group shares at a glance

• Key figures

Information last updated 2024-12-12.

Latest market close	$1.70
52-week range	$0.60 - $7.63
50-day moving average more info button	$1.93
200-day moving average more info button	$1.63
Wall St. target price	$20.00
PE ratio more info button	N/A
Dividend yield more info button	N/A
Earnings per share (TTM) more info button	$-2.61

Is it a good time to buy Virax Biolabs Group stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Virax Biolabs Group price performance over time

Historical closes compared with the close of $1.57 from 2024-12-13

1 week (2024-12-11)	-7.65%
1 month (2024-11-18)	-16.49%
3 months (2024-09-18)	-41.64%
6 months (2024-06-18)	-8.72%

1 year (2023-12-18)	12.14%
2 years (2022-12-16)	-75.91%
3 years (2021-12-14)	N/A
5 years (2019-12-14)	N/A

Virax Biolabs Group financials

Revenue TTM	$156,419
Gross profit TTM	$-1,365
Return on assets TTM	-49.9%
Return on equity TTM	-95.98%
Profit margin	0%
Book value	$2.09
Market Capitalization more info button	$7.4 million

TTM: trailing 12 months

Virax Biolabs Group share dividends

We're not expecting Virax Biolabs Group to pay a dividend over the next 12 months.

Have Virax Biolabs Group's shares ever split?

Virax Biolabs Group's shares were split on a 1:10 basis on 17 December 2023 . So if you had owned 10 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Virax Biolabs Group shares – just the quantity. However, indirectly, the new 900% higher share price could have impacted the market appetite for Virax Biolabs Group shares which in turn could have impacted Virax Biolabs Group's share price.

Virax Biolabs Group share price volatility

Over the last 12 months, Virax Biolabs Group's shares have ranged in value from as little as $0.6 up to $7.63. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Virax Biolabs Group's is 1.925. This would suggest that Virax Biolabs Group's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Virax Biolabs Group overview

Virax Biolabs Group Limited, a biotechnology company, distributes, markets, and sells diagnostics test kits for the prevention, detection, diagnosis, and risk management of viral diseases in the field of immunology. The company provides rapid antibody IgC/IgM tests, antigen tests, polymerase chain reaction rapid tests, and neutralizing antibody tests under the ViraxClear brand name. It also develops T-Cell IVD test kit for COVID-19, which intend to adapt for immunological profiling against multiple viral threats under the ViraxImmune Brand, as well as a proprietary mobile application for ViraxImmune that presents an individual's immunological profiling data and provide advice on the users' immune system. It serves clinics, pharmacies, laboratories, hospitals, and other groups, as well as corporations, pharmaceutical companies, research institutions, hospital systems, and public and private institutions. The company operates in Europe, South America, the Asia Pacific, Sub-Saharan Africa, and internationally. The company was formerly known as Virax Biolabs (Cayman) Limited and changed its name to Virax Biolabs Group Limited in September 2021. Virax Biolabs Group Limited was founded in 2013 and is headquartered in Lanarkshire, the United Kingdom.

Frequently asked questions

What percentage of Virax Biolabs Group is owned by insiders or institutions?
Currently 7.069% of Virax Biolabs Group shares are held by insiders and 5.374% by institutions. How many people work for Virax Biolabs Group?
Latest data suggests 17 work at Virax Biolabs Group. When does the fiscal year end for Virax Biolabs Group?
Virax Biolabs Group's fiscal year ends in March. Where is Virax Biolabs Group based?
Virax Biolabs Group's address is: BioCity Glasgow, Lanarkshire, United Kingdom, ML1 5UH